Oric Pharmaceuticals, Inc. — fact timeline

Oric Pharmaceuticals, Inc. shareholders approved Advisory Vote on the Frequency of Future Stockholder Advisory Votes on the Compensation of the Company’s Named Executive Officers at the 2026-06-18 meeting.

“Proposal 5 - Advisory Vote on the Frequency of Future Stockholder Advisory Votes on the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on an advisory (non-binding) basis, for the frequency of future stockholder advisory votes regarding executive compensation to be held every one year. In accordance with the recommendation of the Company’s board of directors and the voting results of the Company’s stockholders on this non-binding, advisory vote, the Company will hold an advisory (non-binding) vote on the compensation of the Company’s named executive officers on an annual basis. The next non-binding, advisory vote on the frequency of future stockholder advisory votes on the compensation of the Company’s named execute officers will take place no later than the Company’s annual meeting of stockholders in 2032. The tabulation of votes on this matter was as follows: For One Year For Two Years For Three Years Abstain Broker Non-Votes 89,392,979 6,9”

Oric Pharmaceuticals, Inc. shareholders approved Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2026-06-18 meeting.

“Proposal 4 - Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on an advisory (non-binding) basis, executive compensation. The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 88,453,809 1,250,074 2,373 4,865,025”

Oric Pharmaceuticals, Inc. shareholders approved Approval of the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan, as Amended and Restated at the 2026-06-18 meeting.

“Proposal 3 - Approval of the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan, as Amended and Restated The Company’s stockholders approved the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan, as amended and restated. The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 61,228,918 27,264,875 1,212,463 4,865,025”

Oric Pharmaceuticals, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-18 meeting.

“Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 94,536,096 34,641 544 0”

Oric Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2026-06-18 meeting.

“Proposal 1 - Election of Directors The Company’s stockholders elected each of the following nominees to serve as a Class III director, to hold office until the Company’s 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier death, resignation or removal. The tabulation of votes on this matter was as follows: Nominees For Withheld Broker Non-Votes Jacob M. Chacko, M.D. 89,298,150 408,106 4,865,025 Mardi C. Dier 82,007,899 7,698,357 4,865,025”

Oric Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2026.

“ORIC Pharmaceuticals, Inc. (the “Company”), issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026.”

Oric Pharmaceuticals, Inc. announced a restructuring with charges of approximately $1.9 million affecting discovery research group (approximately 20% workforce reduction).

“On August 12, 2025, the Company initiated a strategic pipeline prioritization to focus operational and financial resources on the continued advancement of its two lead clinical programs, ORIC-944 and ORIC-114. This initiative will result in a substantial decrease in preclinical research, primarily from the elimination of the Company’s discovery research group. This will result in an approximately 20% workforce reduction and the Company expects to incur a one-time cost of approximately $1.9 million primarily related to termination benefits, including severance and healthcare-related benefits.”

Oric Pharmaceuticals, Inc. reported financial results for for the quarter ended March 31, 2024.

“ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.”

Oric Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

“On March 11, 2024, ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.”

Oric Pharmaceuticals, Inc. entered into Purchase Agreement with the purchasers named therein valued at 12,500,000 shares at $10.00 per Share, approximately $125 million aggregate gross proceeds (effective 2024-01-20).

“On January 20, 2024, ORIC Pharmaceuticals, Inc. (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of 12,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at $10.00 per Share.”

Oric Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2023.

“ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.”

Oric Pharmaceuticals, Inc. reported financial results for the fiscal quarter ended June 30, 2023.

“ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended June 30, 2023.”

Oric Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the Purchasers named therein valued at approximately $85 million aggregate gross proceeds (effective 2023-06-24).

“On June 24, 2023, ORIC Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 9,285,710 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at $7.00 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 2,857,142 shares of Common Stock (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrants, the “Securities”), at a purchase price of $6.9999 per Pre-Funded Warrant.”

Oric Pharmaceuticals, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm at the 2023-06-14 meeting.

“The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based on the following results of voting:”

Oric Pharmaceuticals, Inc. shareholders approved Election of Class III directors at the 2023-06-14 meeting.

“Each of the following nominees was elected to serve as a Class III director, to hold office until the Company’s 2026 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal:”

Oric Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2023.

“On May 8, 2023, ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2023.”

Oric Pharmaceuticals, Inc.: The Board approved Amended and Restated Bylaws to enhance procedural mechanics and disclosure requirements for stockholder nominations, update provisions for universal proxy rules, conform to DGCL amendments, revise director/committee/officer provisions, clarify exclusive forum, and make conforming (effective 2023-03-20).

“On March 20, 2023, the Board of Directors (the “Board”) of ORIC Pharmaceuticals, Inc. (the “Company”) approved the Company’s Amended and Restated Bylaws (the “Amended and Restated Bylaws”). The Amended and Restated Bylaws were amended and restated to, among other things: • enhance procedural mechanics and disclosure requirements in connection with stockholder nominations of directors and submissions of proposals regarding other business at the Company’s annual meeting of stockholders (except for proposals properly made in accordance with Rule 14a-8 under the Securities Exchange Act of 1934), including by requiring additional background information and disclosures regarding proposing stockholders, proposed nominees and business, and other persons related to a stockholder’s solicitation of proxies; • change certain provisions relating to stockholder nominees for election as a director to address the universal proxy rules adopted by the Securities and Exchange Commission; • revise certain”

Oric Pharmaceuticals, Inc. reported financial results for fourth quarter and full year ended December 31, 2022.

“ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter and year ended December 31, 2022.”

Oric Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2022.

“ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended September 30, 2022.”

Angie You was appointed as director at Oric Pharmaceuticals, Inc..

“On November 9, 2021, the Board appointed Angie You, Ph.D. to serve as a Class II director, with a term expiring at the Company’s 2022 annual meeting of stockholders, as well as serve as a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee.”

Carl Gordon resigned as director at Oric Pharmaceuticals, Inc..

“On November 9, 2021, Carl Gordon, Ph.D., C.F.A. submitted his resignation as a director of ORIC Pharmaceuticals, Inc.”